Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Receivables (2023 - 2025)

CG Oncology filings provide 3 years of Receivables readings, the most recent being $688000.0 for Q4 2025.

  • On a quarterly basis, Receivables changed N/A to $688000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $688000.0, a N/A change, with the full-year FY2025 number at $688000.0, changed N/A from a year prior.
  • Receivables hit $688000.0 in Q4 2025 for CG Oncology, up from $515000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $688000.0 in Q4 2025 to a low of $92000.0 in Q4 2023.
  • Median Receivables over the past 3 years was $263500.0 (2024), compared with a mean of $334250.0.
  • The widest YoY moves for Receivables: up 275.91% in 2025, down 125.49% in 2025.
  • CG Oncology's Receivables stood at $92000.0 in 2023, then soared by 48.91% to $137000.0 in 2024, then skyrocketed by 402.19% to $688000.0 in 2025.
  • The last three reported values for Receivables were $688000.0 (Q4 2025), $515000.0 (Q3 2025), and $562000.0 (Q2 2025) per Business Quant data.